Access your copy today:
Corneal transplant patients with previous graft failure(s) face an increased risk of corneal transplant rejection due to neovasularization (NV). Fortunately, a new gene therapy shows promise in preventing NV.
Our case study, "New data support the safety and efficacy of an anti-angiogenic gene therapy for reducing neovascularization of corneal transplants," discusses a recent study utilizing pONYK1EiA- modified rabbit corneas in a rabbit corneal transplant model.
The study confirms the efficacy of the genetically modified corneas and also provides safety data for a three-month GLP toxicology and biodistribution study of these corneas in a rabbit corneal transplant model. This may lead to first in-human trials to prevent NV and increase the corneal transplantation success rate.
When implanted in rabbit models, the genetically modified donor corneas (OXB-202) were:
- Safe and well-tolerated
- Featured a favorable immunogenicity profile
- Expressed robust levels of endostatin and angiostatin
Complete the form to learn about an encouraging new gene therapy for preventing corneal graft rejection due to NV.
